Literature DB >> 10906803

Age related seroprevalence of antibodies to varicella in India.

M R Lokeshwar1, A Agrawal, S D Subbarao, M S Chakraborty, A V Ram Prasad, J Weil, H L Bock, S Kanwal, R C Shah, N Shah.   

Abstract

OBJECTIVE: To determine the age related prevalence of Varicella Zoster Virus (VZV) antibodies in India.
SETTING: This was a cross sectional multicentric study performed in 4 major cities of India: Calcutta (outpatients), Mumbai (outpatients), Lucknow (walk-in patients to a diagnostic laboratory, orphanage and factory workers) and Bangalore (outpatients and walk-in patients to a diagnostic laboratory).
METHODS: A total of 1609 volunteers from birth to 40 years of age were included into the study. IgG antibodies against VZV were determined using commercial kits (ELISA-Enzygnost).
RESULTS: Overall seroprevalence of anti VZV antibodies was 68. 22percnt. The age related seroprevalence rate of anti VZV antibodies was 29percnt in the age group of 1-5 years, 51.1percnt in 5-10 years, 71.7percnt in 11-15 years, 79.8percnt in 16-20 years, 88.1percnt in 21-30 years and 91.1percnt in 31-40 years.
CONCLUSION: A significant proportion of adolescents and adults are susceptible to varicella in India, as in other tropical countries

Entities:  

Mesh:

Year:  2000        PMID: 10906803

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  24 in total

1.  Monitoring prevalence of varicella-zoster virus clades in Germany.

Authors:  A Sauerbrei; J Stefanski; A Philipps; A Krumbholz; R Zell; P Wutzler
Journal:  Med Microbiol Immunol       Date:  2010-10-31       Impact factor: 3.402

2.  Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.

Authors:  Anand Prakash Dubey; Mohammad Moonis Akbar Faridi; Monjori Mitra; Iqbal Rajinder Kaur; Aashima Dabas; Jaydeep Choudhury; Mallar Mukherjee; Devendra Mishra
Journal:  Hum Vaccin Immunother       Date:  2017-05-16       Impact factor: 3.452

Review 3.  Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.

Authors:  A Sauerbrei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

4.  Infection control best practices in clinical research in resource-limited settings.

Authors:  Catherine Godfrey; Jeffrey T Schouten
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

5.  Neonatal varicella: A case report.

Authors:  Ak Bhardwaj; Pd Sharma; A Sharma
Journal:  Australas Med J       Date:  2011-06-30

Review 6.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

7.  The seroepidemiology of varicella zoster virus among pregnant Bangladeshi and white British women in the London Borough of Tower Hamlets, UK.

Authors:  Y S Talukder; G Kafatos; A Pinot de Moira; J Aquilina; S P Parker; N S Crowcroft; D W G Brown; J Breuer
Journal:  Epidemiol Infect       Date:  2007-04-20       Impact factor: 2.451

8.  Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002.

Authors:  Gustavo H Dayan; María S Panero; Roberto Debbag; Ana Urquiza; Marta Molina; Susana Prieto; María Del Carmen Perego; Graciela Scagliotti; Diana Galimberti; Guillermo Carroli; Cristina Wolff; D Scott Schmid; Vladimir Loparev; Dalya Guris; Jane Seward
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

9.  Study of susceptibility towards varicella by screening for the presence of IgG antibodies among nursing and medical students of a tertiary care teaching hospital in pune, India.

Authors:  Samir A Singru; Vijay W Tilak; N Gandham; Jitendra S Bhawalkar; Sudhir L Jadhav; Harshal T Pandve
Journal:  J Glob Infect Dis       Date:  2011-01

10.  Household size is critical to varicella-zoster virus transmission in the tropics despite lower viral infectivity.

Authors:  Richard A Nichols; Karin T Averbeck; Anja G Poulsen; Mahmoud M al Bassam; Fernando Cabral; Peter Aaby; Judith Breuer
Journal:  Epidemics       Date:  2010-12-07       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.